Loading…
Swiss contract manufacturer of peptides and oligonucleotides used in drugs, including GLP-1 obesity/diabetes medicines.
Swiss contract manufacturer of peptides and oligonucleotides used in drugs, including GLP-1 obesity/diabetes medicines.
Makes peptides, short chains of amino acids, to order for drugmakers, from small clinical batches through to commercial supply, with the commercial stage earning the most once a drug is approved. Demand has been driven by makers of GLP-1 medicines, so large commercial programmes weigh heavily. It has been building large new capacity in Switzerland.
In one line: A peptide-focused CDMO, like a smaller Lonza specializing in peptides.
Moat: narrow (process know-how, customer qualification, scale). Large-scale, regulatory-qualified peptide-synthesis capacity is hard and slow to replicate.
Headquarters: Bubendorf, Switzerland · Founded: 1971 · Employees: 2,511
Size Bachem (BANB.SW) is a Switzerland Health Care company (Pharmaceuticals: Major) with a market value of $7.32B, the 43rd largest of 158 Switzerland companies the cockpit tracks. Shares closed at CHF 79.70 on 6 Nov 2026.
Performance Over six months the shares gained 3.2%, against +6.7% for the median peer and +11.6% for the Switzerland market (cap-weighted) — 10th lowest of 21 in its peer set.
Growth Revenue grew 4.5% over the last twelve months (peer median +10.4%); the operating margin is 19.4% (peer median 16.4%).
Valuation It trades at 33.1× forward earnings against a peer median of 16.4× (4th most expensive of 14).
Capital Return on invested capital runs 1.9 points above its cost of capital (5.0% WACC).
Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CHF 709M | CHF 695M | CHF 605M | CHF 577M | CHF 532M |
| Revenue growth | — | +15% | +5% | +9% | — |
| Gross profit | CHF 191M | CHF 200M | CHF 183M | CHF 177M | CHF 171M |
| EBITDA | CHF 190M | CHF 190M | CHF 175M | CHF 166M | CHF 160M |
| Net income | CHF 149M | CHF 149M | CHF 120M | CHF 112M | CHF 101M |
| Free cash flow | -CHF 47.4M | -CHF 48.2M | -CHF 127M | -CHF 13.8M | -CHF 45.9M |
| Capital expenditure | CHF 348M | CHF 329M | CHF 285M | CHF 268M | CHF 142M |
| Total debt | n/a | CHF 57.4M | CHF 290,000 | CHF 401,000 | CHF 691,000 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Bachem BANB.SW | $7.32B | +3% | +5% | 19% | 33.1× | n/a |
| Lonza LONN.SW | $55.4B | +39% | -11% | 25% | 36.1× | 15.0% |
| PolyPeptide PPGN.SW | $1.62B | +6% | +22% | 7% | 51.3× | n/a |
| Novo Nordisk A/S NOVO-B.CO | $190B | -7% | +6% | 48% | 11.9× | 0.1% |
| Siegfried SFZN.SW | $3.98B | -10% | +4% | 16% | 17.8× | n/a |
| Wuxi Apptec 2359.HK | $66.3B | +40% | +38% | 44% | 20.4× | 8.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | BANB.SW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +2.3% | +5.7% | 7th lowest of 21 |
| 6-month return | +3.2% | +6.7% | 10th lowest of 21 |
| Distance from 52-week high | -7.3% | -13.7% | 6th highest of 21 |
| Revenue growth (TTM) | +4.5% | +10.4% | 8th lowest of 20 |
| Operating margin | 19.4% | 16.4% | 7th highest of 19 |
| Forward P/E | 33.1× | 16.4× | 4th most expensive of 14 |
| ROIC minus cost of capital | +1.9 pp | +4.4 pp | 10th lowest of 20 |
| EV / EBITDA | 32.4× | 17.4× | 4th most expensive of 12 |
| Net debt / EBITDA | 0.8× | -0.6× | 4th most indebted of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Bachem BANB.SW | Switzerland | $7.32B | +3% | +5% | 19% | 33.1× | n/a | n/a |
| Huadong Medicine 000963.SZ | China | $7.29B | -17% | +2% | 9% | 14.0× | -2.7% | +5.3% |
| Kiniksa Pharmaceuticals International KNSA | United States | $7.37B | +60% | +58% | 14% | 61.7× | 9.9% | +45.5% |
| Cytokinetics CYTK | United States | $7.46B | -30% | -21% | -1,046% | n/a | n/a | n/a |
| Grifols GRF.MC | Spain | $7.49B | +23% | 0% | 16% | 13.0× | 6.8% | +7.1% |
| Amneal Pharmaceuticals AMRX | United States | $7.01B | +53% | +9% | 17% | 17.7× | 15.2% | +8.7% |
| ONO Pharmaceutical 4528.T | Japan | $7.01B | +2% | -2% | 22% | 14.7× | -8.2% | +10.8% |
| Alkermes Public ALKS | United States | $7.71B | +31% | +15% | 5% | n/a | 31.5% | +7.3% |
| Glenmark Pharmaceuticals GLENMARK.NS | India | $7.73B | +9% | +33% | 20% | 32.0× | 20.0% | +9.4% |
| RemeGen 9995.HK | Hong Kong | $6.92B | -31% | +293% | 61% | 7.4× | -4.8% | +57.9% |
| Praxis Precision Medicines PRAX | United States | $7.75B | -16% | -100% | n/a | n/a | n/a | n/a |
| Rhythm Pharmaceuticals RYTM | United States | $7.78B | +19% | +61% | -67% | n/a | n/a | n/a |
| Oruka Therapeutics ORKA | United States | $6.81B | +59% | n/a | n/a | n/a | n/a | n/a |
| Corcept Therapeutics CORT | United States | $7.96B | +39% | +30% | 12% | 16.4× | 24.9% | +16.6% |
| H. Lundbeck A/S HLUN-A.CO | Denmark | $8.02B | +47% | +9% | 27% | n/a | -9.1% | +6.6% |
| Alkem Laboratories ALKEM.NS | India | $6.67B | -5% | +13% | 17% | 27.4× | 24.3% | +10.7% |
| Kyowa Kirin 4151.T | Japan | $8.05B | +4% | +10% | 24% | 15.6× | -6.1% | +9.3% |
| Asymchem Laboratories (Tianjin) 002821.SZ | China | $8.07B | +23% | +18% | 17% | 41.4× | n/a | n/a |
| ALK-abello A/S ALK-B.CO | Denmark | $8.14B | -5% | +17% | 27% | 35.7× | 7.6% | +12.6% |
| Ionis Pharmaceuticals IONS | United States | $6.55B | -48% | -7% | -68% | n/a | n/a | n/a |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | China | $6.48B | 0% | +4% | 14% | 12.8× | -6.3% | +18.4% |